Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.
More...
Linear Mode
